Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Asian Pharma Groups Agree to Ensure Smooth Drug Reviews amid COVID-19 Crisis
Initiatives to harmonize regulatory approval systems in Asia continue unabated despite the COVID-19 pandemic raging on across the world. The Asia Partnership Conference of Pharmaceutical Associations (APAC) agreed on the importance of keeping regulatory reviews going during the crisis at…
To read the full story
Related Article
- APAC Disbands Drug Discovery WG as Asia Capabilities Rise
April 23, 2026
- Asian Pharma Groups Adopt Position Paper to Push E-Labeling
April 20, 2023
- Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
April 7, 2022
ORGANIZATION
- BMS Prods Japan to Better Reward Regenerative Medicine Innovation
September 11, 2026
- Prix Galien to Launch Japan Awards in February 2027
September 8, 2026
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- UA Zensen Manufacturing Wage Hikes at 4.89%, Pharma in Mid-4% Range
September 4, 2026
- LINK-J Eyes Stronger Ties with AI, Semiconductor Sectors
September 2, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…